MapLight Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed August 3, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
An investor acquired 1,209,225 shares of MapLight Therapeutics voting common stock over three days in late July 2026: 206,225 shares on July 28 at $11.04 weighted average ($2.3M), 3,000 shares on July 29 at $12.63 ($37.9K), and 1,000,000 shares on July 30 at $13.00 ($13.0M). Total investment ≈ $15.4M at prices ranging from $10.295 to $13.00 per share, all purchased in open market through broker-dealer.
Why this rating
Aggregate $15.4M acquisition is 3.7% of company's $418.8M asset base—material but typical institutional accumulation. No control change disclosed.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.